Inovio rises after promising Q2 results

[Quarterly results]
CharlieAJA/iStock via Getty Images

Inovio Pharmaceuticals (NASDAQ:INO [https://seekingalpha.com/symbol/INO]) shares up after the company's net loss lowered in Q2 from the previous year period.

The company reported a second quarter 2025 net loss of $0.61 per share, lower than last year's second quarter net loss of $1.19 per share. This compared to consensus of $0.61 per share which was in line.

As of June 30, 2025, Inovio's cash, cash equivalents and short-term investments were $47.5M.

The company said it is on track to submit the marketing application for INO-3107, its respiratory papillomatosis treatment, in the second half of the year and targeting file acceptance by year-end.

The stock is up about 10% so far today.

MORE ON INOVIO PHARMACEUTICALS

* Inovio Pharmaceuticals, Inc. (INO) Q2 2025 Earnings Call Transcript [https://seekingalpha.com/article/4812966-inovio-pharmaceuticals-inc-ino-q2-2025-earnings-call-transcript]
* Inovio aims for BLA submission and FDA file acceptance by year-end 2025 as 3107 data shows sustained surgery reduction [https://seekingalpha.com/news/4484419-inovio-aims-for-bla-submission-and-fda-file-acceptance-by-year-end-2025-as-3107-data-shows]
* Inovio Pharmaceuticals Q2 2025 Earnings Preview [https://seekingalpha.com/news/4483280-inovio-pharmaceuticals-q2-2025-earnings-preview]
* Seeking Alpha’s Quant Rating on Inovio Pharmaceuticals [https://seekingalpha.com/symbol/INO/ratings/quant-ratings]
* Financial information for Inovio Pharmaceuticals [https://seekingalpha.com/symbol/INO/income-statement]